Minerva Neurosciences, Inc. (NERV) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$2.41

From 52W high−69.52%

Volume10821.00

Market cap$117.46M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$2.41

From 52W high

−69.52%

Volume

10821.00

Market cap

$117.46M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

37.1

MomentumView details →

1D Return

+4.68%

YTD Return

−40.06%

SummaryUpdated Jun 1, 2026

Minerva Neurosciences, Inc. (NASDAQ:NERV) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Cyrenaic Pharmaceuticals, Inc., the company changed its name to Minerva Neurosciences in 2013 and went public in July 2014. The company focuses on developing treatments for central nervous system diseases, with its lead drug candidate roluperidone targeting schizophrenia symptoms. Minerva operates as a development-stage company without commercial products, relying on partnerships and licensing agreements to advance its pipeline.

Ask drillr about Minerva Neurosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−0.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

195.65%

ROA (TTM)

−414.72%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+4.68%

YTD Return

−40.06%

1Y Return

−34.35%

RSI (14)

37.1

vs 50D SMA

−28.96%

vs 200D SMA

−50.62%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

20.14x

Quick Ratio

20.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.14

EPS Surprise

27.58%

Beats (12Q)

7/12

Next Q EPS Est

−$0.16

Avg Surprise (4Q)

12.17%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−394.35M

Op. CF (TTM)

−18.78B

Next earningsNov 4, 2026 →

Latest newsMore news →

Minerva Neurosciences reported Q2 2026 results with a net loss of $17.5 million and diluted EPS of -$0.14, including $7.2 million in R&D expenses and $3.5 million in G&A expenses.90d ago

Similar companies

Molecular Partners AGMOLN Voyager Therapeutics, Inc.VYGR Kazia Therapeutics LimitedKZIA Equillium, Inc.EQ Neumora Therapeutics, Inc. Common StockNMRA PolyPid Ltd.PYPD Find similar companies →

Latest newsMore news →

Minerva Neurosciences reported Q2 2026 results with a net loss of $17.5 million and diluted EPS of -$0.14, including $7.2 million in R&D expenses and $3.5 million in G&A expenses.90d ago